Enlivex Therapeutics (ENLV) Short Interest Ratio & Short Volume → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free ENLV Stock Alerts $1.40 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Enlivex Therapeutics Short Interest DataCurrent Short Volume263,200 sharesPrevious Short Volume278,700 sharesChange Vs. Previous Month-5.56%Dollar Volume Sold Short$439,544.00Short Interest Ratio / Days to Cover1.5Last Record DateApril 30, 2024Outstanding Shares18,600,000 sharesPercentage of Shares Shorted1.42%Today's Trading Volume44,202 sharesAverage Trading Volume150,109 sharesToday's Volume Vs. Average29% Short Selling Enlivex Therapeutics ? Sign up to receive the latest short interest report for Enlivex Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatENLV Short Interest Over TimeENLV Days to Cover Over TimeENLV Percentage of Float Shorted Over Time Ad Stansberry ResearchThe Presidential candidate you should REALLY be worried aboutThe Presidential candidate you should REALLY be worried about Most Americans are overlooking the seemingly impossible candidate that should worry you. It's not Biden… Trump… Newsom… or even Michelle. It's someone even worse. New evidence of a secret plan indicates he could soon return, and finish what he started.Get the full story right here. Enlivex Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024263,200 shares $439,544.00 -5.6%N/A1.5 $1.67 4/15/2024278,700 shares $362,310.00 +17.9%N/A1.6 $1.30 3/31/2024236,400 shares $895,956.00 -9.6%N/A2.7 $3.79 3/15/2024261,500 shares $1.07 million +15.4%N/A2.4 $4.11 2/29/2024226,600 shares $703,593.00 +51.2%N/A2.2 $3.11 2/15/2024149,900 shares $481,179.00 -6.6%N/A1.6 $3.21 Get the Latest News and Ratings for ENLV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024160,500 shares $449,400.00 -13.7%N/A1.9 $2.80 1/15/2024185,900 shares $533,533.00 +32.5%N/A2.3 $2.87 12/31/2023140,300 shares $378,810.00 +36.0%N/A1.8 $2.70 12/15/2023103,200 shares $145,512.00 -6.3%N/A1.9 $1.41 11/30/2023110,100 shares $202,584.00 -0.9%N/A3.5 $1.84 11/15/2023111,100 shares $194,425.00 -6.2%N/A3.6 $1.75 10/31/2023118,400 shares $157,472.00 +13.1%N/A3.9 $1.33 10/15/2023104,700 shares $147,627.00 -8.1%N/A4.1 $1.41 9/30/2023113,900 shares $179,962.00 +4.4%N/A4.5 $1.58 9/15/2023109,100 shares $206,199.00 +3.4%N/A4.2 $1.89 8/31/2023105,500 shares $252,145.00 -9.3%N/A4.8 $2.39 8/15/2023116,300 shares $303,543.00 +2.4%N/A5.1 $2.61 7/31/2023113,600 shares $290,816.00 +8.6%N/A4.9 $2.56 7/15/2023104,600 shares $248,948.00 +2.5%N/A4.8 $2.38 6/30/2023102,100 shares $268,247.33 -20.2%N/A3.6 $2.63 6/15/2023128,000 shares $362,240.00 +5.6%N/A3.6 $2.83 5/31/2023121,200 shares $316,332.00 -5.8%N/A3.5 $2.61 5/15/2023128,700 shares $359,073.00 -1.2%N/A3.8 $2.79 4/30/2023130,200 shares $369,768.00 -4.6%N/A3.7 $2.84 4/15/2023136,400 shares $396,924.00 -15.7%N/A3.6 $2.91 3/31/2023161,700 shares $588,588.00 +0.5%N/A4.3 $3.64 3/15/2023160,900 shares $577,631.00 -1.3%N/A5.9 $3.59 2/28/2023163,000 shares $652,000.00 +0.9%N/A5.7 $4.00 2/15/2023161,500 shares $673,455.00 -8.8%N/A5.5 $4.17 1/31/2023177,100 shares $775,698.00 -2.9%N/A5.8 $4.38 1/15/2023182,300 shares $796,505.16 -4.8%N/A6.9 $4.37 12/30/2022191,400 shares $753,637.50 -0.5%N/A7.8 $3.94 12/15/2022192,400 shares $779,220.00 -11.5%N/A9.2 $4.05 11/30/2022217,500 shares $996,998.25 +16.9%N/A9 $4.58 11/15/2022186,000 shares $894,660.00 +0.1%N/A6.9 $4.81 10/31/2022185,800 shares $797,082.00 -3.8%N/A6.6 $4.29 10/15/2022193,100 shares $805,227.00 +1.2%N/A5.4 $4.17 9/30/2022190,900 shares $811,325.00 +4.5%N/A4.4 $4.25 9/15/2022182,700 shares $959,175.00 -5.4%N/A3.9 $5.25I’m afraid WWIII is a very real possibility (Ad)As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film.Take a look. ENLV Short Interest - Frequently Asked Questions What is Enlivex Therapeutics' current short interest? Short interest is the volume of Enlivex Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 263,200 shares of ENLV short. Learn More on Enlivex Therapeutics' current short interest. What is a good short interest ratio for Enlivex Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ENLV shares currently have a short interest ratio of 2.0. Learn More on Enlivex Therapeutics's short interest ratio. Is Enlivex Therapeutics' short interest increasing or decreasing? Enlivex Therapeutics saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 263,200 shares, a decrease of 5.6% from the previous total of 278,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Enlivex Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Enlivex Therapeutics: JanOne Inc. (2.00%), Biora Therapeutics, Inc. (4.52%), Acasti Pharma Inc. (0.02%), Unity Biotechnology, Inc. (2.16%), Oncternal Therapeutics, Inc. (0.49%), DURECT Co. (3.24%), Lipocine Inc. (3.49%), Iterum Therapeutics plc (7.68%), Forte Biosciences, Inc. (0.08%), Lisata Therapeutics, Inc. (0.22%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Enlivex Therapeutics stock? Short selling ENLV is an investing strategy that aims to generate trading profit from Enlivex Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enlivex Therapeutics? A short squeeze for Enlivex Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ENLV, which in turn drives the price of the stock up even further. How often is Enlivex Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENLV, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: JanOne Short Squeeze Biora Therapeutics Short Squeeze Acasti Pharma Short Squeeze Unity Biotechnology Short Squeeze Oncternal Therapeutics Short Squeeze DURECT Short Squeeze Lipocine Short Squeeze Iterum Therapeutics Short Squeeze Forte Biosciences Short Squeeze Lisata Therapeutics Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENLV) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchElon’s New Device is About to Shock the WorldInvestorPlaceMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits